Trials / Conditions / Moderate to Severe Glabellar Lines

Moderate to Severe Glabellar Lines

13 registered clinical trials studyying Moderate to Severe Glabellar Lines — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Line NCT07427797	Ipsen	Phase 3
Recruiting	A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle NCT07435428	Ipsen	Phase 3
Recruiting	Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe NCT06937944	JHM BioPharma (Tonghua) Co. , Ltd.	Phase 3
Recruiting	A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines NCT06481475	Chongqing Claruvis Pharmaceutical Co., Ltd.	Phase 2
Active Not Recruiting	A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injectio NCT06583486	Chongqing Claruvis Pharmaceutical Co., Ltd.	Phase 3
Completed	A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, NCT06199336	JHM BioPharma (Tonghua) Co. , Ltd.	Phase 1 / Phase 2
Completed	Study of AGN-151586 in Japanese Participants With Moderate to Severe Glabellar Lines NCT06151561	AbbVie	Phase 1
Completed	A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in t NCT06499688	Chongqing Claruvis Pharmaceutical Co., Ltd.	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lin NCT05463965	Galderma R&D	Phase 3
Completed	A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lin NCT05743634	Chongqing Claruvis Pharmaceutical Co., Ltd.	Phase 1 / Phase 2
Completed	DWP450 for Treating Moderate to Severe Glabellar Lines NCT06354127	Daewoong Pharmaceutical Co. LTD.	Phase 3
Completed	Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subject NCT03970876	EuBiologics Co.,Ltd	Phase 1 / Phase 2
Completed	Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabella NCT02353871	Ipsen	Phase 3